PMID- 34302695
OWN - NLM
STAT- MEDLINE
DCOM- 20211013
LR  - 20220725
IS  - 2212-5469 (Electronic)
IS  - 1738-2696 (Print)
IS  - 1738-2696 (Linking)
VI  - 18
IP  - 5
DP  - 2021 Oct
TI  - Osteogenic and Angiogenic Potency of VEGF165-Transfected Canine Bone Marrow 
      Mesenchymal Cells Combined with Coral Hydroxyapatite in Vitro.
PG  - 875-886
LID - 10.1007/s13770-021-00368-7 [doi]
AB  - BACKGROUND: To explore the osteogenic and angiogenic potential of human vascular 
      endothelial growth factor 165 (hVEGF165) gene-transfected canine bone marrow 
      mesenchymal stem cells (BMSCs) combined with coral hydroxyapatite (CHA) scaffold. 
      METHODS: We constructed a lentiviral vector and transfected canine BMSCs with the 
      best multiplicity of infection. Osteogenesis was induced in the transfected 
      groups (GFP-BMSCs group and hVEGF-BMSCs group) and non-transfected group (BMSCs 
      group), followed by the evaluation of alkaline phosphatase (ALP) activity and 
      alizarin red S staining. Cells from the three groups were co-cultured with CHA 
      granules, respectively to obtain the tissue-engineered bone. MTT assay and 
      fluorescence microscopy were employed to assess cell proliferation and adhesion. 
      The expression of osteogenic and angiogenic related genes and proteins were 
      evaluated at 7, 14, 21, and 28 days post osteoinduction in cell culture alone and 
      cell co-culture with CHA, respectively using RT-PCR and ELISA. RESULTS: The 
      hVEGF165 gene was transfected into BMSCs successfully. Higher ALP activity and 
      more calcified nodules were found in the hVEGF-BMSCs group than in the control 
      groups (p < 0.001). Cells attached and proliferated in CHA particles. Both cells 
      cultured alone and cells co-culture with CHA expressed more osteogenic and 
      angiogenic related genes and proteins in the hVEGF-BMSCs group compared to the 
      GFP-BMSCs and BMSCs groups (p < 0.05). CONCLUSION: High expression of hVEGF165 in 
      BMSCs potentially promote the osteogenic potential of BMSCs, and synergically 
      drive the expression of other osteogenic and angiogenic factors. hVEGF-BMSCs 
      co-cultured with CHA expressed more osteogenic and angiogenic related factors, 
      creating a favorable microenvironment for osteogenesis and angiogenesis. Also, 
      the findings have allowed for the construction of a CHA-hVEGF-BMSCs 
      tissue-engineered bone.
CI  - (c) 2021. The Korean Tissue Engineering and Regenerative Medicine Society.
FAU - Zhang, Quanyin
AU  - Zhang Q
AD  - Stomatological Hospital, Southern Medical University, S366 Jiangnan Boulevard, 
      Guangzhou, 510280, China.
FAU - Zhang, Jie
AU  - Zhang J
AD  - Stomatological Hospital, Southern Medical University, S366 Jiangnan Boulevard, 
      Guangzhou, 510280, China.
FAU - Chen, Lin
AU  - Chen L
AD  - Stomatological Hospital, Southern Medical University, S366 Jiangnan Boulevard, 
      Guangzhou, 510280, China.
FAU - Fan, Yunjian
AU  - Fan Y
AD  - Stomatological Hospital, Southern Medical University, S366 Jiangnan Boulevard, 
      Guangzhou, 510280, China.
FAU - Long, Jiazhen
AU  - Long J
AD  - Stomatological Hospital, Southern Medical University, S366 Jiangnan Boulevard, 
      Guangzhou, 510280, China.
FAU - Liu, Shuguang
AU  - Liu S
AD  - Stomatological Hospital, Southern Medical University, S366 Jiangnan Boulevard, 
      Guangzhou, 510280, China. Dr.Liusg@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210724
PL  - Korea (South)
TA  - Tissue Eng Regen Med
JT  - Tissue engineering and regenerative medicine
JID - 101699923
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 91D9GV0Z28 (Durapatite)
SB  - IM
MH  - Animals
MH  - Anthozoa/chemistry
MH  - Bone Marrow Cells
MH  - Dogs
MH  - *Durapatite
MH  - Humans
MH  - Mesenchymal Stem Cells/*cytology
MH  - *Osteogenesis/genetics
MH  - Transfection
MH  - *Vascular Endothelial Growth Factor A/genetics
PMC - PMC8440753
OTO - NOTNLM
OT  - Bone marrow mesenchymal stem cells
OT  - Osteogenic and angiogenic properties
OT  - Vascular endothelial growth factor 165
COIS- The authors have no financial conflict of interest.
EDAT- 2021/07/25 06:00
MHDA- 2021/10/14 06:00
PMCR- 2022/07/24
CRDT- 2021/07/24 12:12
PHST- 2021/04/11 00:00 [received]
PHST- 2021/06/16 00:00 [accepted]
PHST- 2021/06/16 00:00 [revised]
PHST- 2021/07/25 06:00 [pubmed]
PHST- 2021/10/14 06:00 [medline]
PHST- 2021/07/24 12:12 [entrez]
PHST- 2022/07/24 00:00 [pmc-release]
AID - 10.1007/s13770-021-00368-7 [pii]
AID - 368 [pii]
AID - 10.1007/s13770-021-00368-7 [doi]
PST - ppublish
SO  - Tissue Eng Regen Med. 2021 Oct;18(5):875-886. doi: 10.1007/s13770-021-00368-7. 
      Epub 2021 Jul 24.